Esmolol
- Generic Name
- Esmolol
- Brand Names
- Brevibloc
- Drug Type
- Small Molecule
- Chemical Formula
- C16H25NO4
- CAS Number
- 81147-92-4
- Unique Ingredient Identifier
- MDY902UXSR
- Background
Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decrea...
- Indication
For the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention.
- Associated Conditions
- Hypertension, Tachycardia, Abnormal ventricular rate, Heart rate abnormal
- Associated Therapies
- -
Evaluation of Early CRRT InTerventions in Patients With ECMO(ELITE)
- Conditions
- Interventions
- First Posted Date
- 2018-06-08
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Beijing Anzhen Hospital
- Target Recruit Count
- 131
- Registration Number
- NCT03549923
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Beijing, China
Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition
- First Posted Date
- 2018-05-23
- Last Posted Date
- 2019-10-17
- Lead Sponsor
- University Hospital Bispebjerg and Frederiksberg
- Target Recruit Count
- 10
- Registration Number
- NCT03533179
- Locations
- 🇩🇰
University Hospital Bispebjerg, Copenhagen, Denmark
Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382
- Conditions
- Interventions
- First Posted Date
- 2017-11-20
- Last Posted Date
- 2018-04-25
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 22
- Registration Number
- NCT03347968
- Locations
- 🇺🇸
Research Site, Daytona Beach, Florida, United States
Esmolol to Control Adrenergic Storm in Septic Shock- ROLL-IN 2
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Samuel Brown
- Target Recruit Count
- 10
- Registration Number
- NCT03208257
- Locations
- 🇺🇸
Intermountain Medical Center, Murray, Utah, United States
The Effect of Intraoperative Labetalol on Time to Discharge
- Conditions
- Interventions
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2020-02-13
- Lead Sponsor
- Dr. Robert Tanzola
- Target Recruit Count
- 172
- Registration Number
- NCT02997800
- Locations
- 🇨🇦
Queen's University, Department of Anesthesiology, Kingston, Ontario, Canada
Hemodynamic Response to Intubation
- First Posted Date
- 2016-07-26
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Ufuk University
- Target Recruit Count
- 60
- Registration Number
- NCT02844894
- Locations
- 🇹🇷
Ufuk University Hospital, Ankara, Turkey
Pilot Study: Echocardiographic and Hemodynamic Effects of Esmolol in Septic Shock Patients
- First Posted Date
- 2016-07-25
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT02842983
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia
- First Posted Date
- 2016-07-22
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- Intermountain Health Care, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT02841241
- Locations
- 🇺🇸
Intermountain Medical Center and Intermountain Clinics, Murray, Utah, United States
The Effect of Esmolol on Clinical Prognosis of Patients With Severe Sepsis
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2016-06-08
- Lead Sponsor
- Fujian Provincial Hospital
- Target Recruit Count
- 151
- Registration Number
- NCT02794025
Esmolol Versus Dexmedetomidine During Intracranial Procedures
- Conditions
- Interventions
- First Posted Date
- 2015-09-30
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- George Papanicolaou Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT02563288
- Locations
- 🇬🇷
George Papanikolaou General Hospital, Thessaloniki, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.